國家級人體生物資料庫整合平台共同資料模式實作指引(NBCT Common Data Model IG)
0.1.0 - trial-use

Publication Build: This will be filled in by the publication tooling

## ValueSet: SSF2 白血病-白血病分子生物學檢查的評估值集

Official URL: https://www.ghd.tw/cdm-fhir/fhir/ValueSet/ssf-2-leukemia-valueset | Version: 0.1.0
Active as of 2024-08-01 | Computable Name: SSF2leukemiaVS

Assessment of molecular studies in leukemia Value Set

References

- Observation CRLF-癌症部位特定因子2(ssf2)

### Logical Definition (CLD)

Generated Narrative: ValueSet ssf-2-leukemia-valueset

- Include all codes defined in `https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem`

### Expansion

Generated Narrative: ValueSet

Expansion based on codesystem SSF2 白血病-白血病分子生物學檢查的評估代碼系統 v0.1.0 (CodeSystem)

This value set contains 33 concepts

Code | System | Display
000 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | 正常
001 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with RUNX1-RUNX1T1
002 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with CBFB-MYH11
003 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | Acute promyelocytic leukemia with PML-RARA
004 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with KMT2A-MLLT3
005 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with DEK-NUP214
006 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with GATA2, MECOM
007 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML(megakaryoblastic) with RBM15-MKL1
008 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with mutated NPM1
009 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with biallelic mutation of CEBPA
010 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with mutated FLT3/ITD
011 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with mutated FLT3/TKD
012 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with MLL-PTD (partial tandem duplication)
013 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with BCR-ABL1
021 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | B lymphoblastic leukemia/lymphoma with BCR-ABL1
022 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged
023 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1)
024 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | B-lymphoblastic leukemia/lymphoma with IGH/IL3
025 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1)
041 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | Mixed phenotype acute leukemia with BCR-ABL1
042 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | Mixed-phenotype acute leukemia with KMT2A-rearranged
051 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | Chronic myelogenous leukemia BCR-ABL1 positive
052 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | JAK2 V617F mutation
053 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | Myeloid and lymphoid neoplasms with PDGFRA rearrangement
054 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | Myeloid and lymphoid neoplasms with PDGFRB rearrangement
055 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | Myeloid and lymphoid neoplasms with FGFR1 rearrangement
090 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | (1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常
091 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | 同時有兩種(含)以上上述之分子檢驗異常
092 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | 同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常
8XX | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | Molecular study after chemotherapy or immunotherapy or target therapy
988 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | 不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4)
998 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | 有執行分子生物學檢查，但結果無法判斷
999 | https://www.ghd.tw/cdm-fhir/fhir/CodeSystem/ssf-2-leukemia-codesystem | (1) 病歷未記載或不詳 (2) 未執行分子生物學檢查

Explanation of the columns that may appear on this page:

Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System | The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code | The code (used as the code in the resource instance)
Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition | An explanation of the meaning of the concept
Comments | Additional notes about how to use the code